東曜藥業(01875.HK)採納受限制股份獎勵計劃
格隆匯5月29日丨東曜藥業(01875.HK)宣佈,其已決議採納受限制股份獎勵計劃。為不時向經選定參與者授出獎勵股份的目的,公司已與各受託人訂立兩份信託契據,以構成與計劃有關的信託。
倘因配發及發行股份予受託人而導致根據計劃所管理的股份數目超過5700萬股(即公司於採納計劃當日的已發行股本的10%)或管理委員會全權酌情釐定的其他限額,則不得根據計劃進行有關配發及發行。單次或累計授予一名經選定參與者的獎勵股份最高數目不得超過570萬股(即公司於採納計劃當日的已發行股本的1%)。
於採納計劃後,董事會亦已決議根據計劃向84名補償性承授人作出涉及3141.38萬股獎勵股份的補償性授出。公司將於股東特別大會上提呈股東決議案,以供獨立股東考慮及酌情批准配發及發行補償性股份。根據於補償性授出日期每股股份的收市價4.45港元,補償性股份的總市值約為1.40億港元。
假設補償性股份悉數歸屬,公司將收取授出代價總額約899.50萬美元(相當於約6971.15萬港元)。公司擬將有關授出代價(扣除相關費用和支出後)用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.